Background & Aim: Benign prostatic hyperplasia (BPH) is one of the prevalent age-related medical conditionin men. In the last 20 years, alternative therapies, especially those based on herbs, are increasingly preferred. The most popularly consumed herb is Serenoa re More
Background & Aim: Benign prostatic hyperplasia (BPH) is one of the prevalent age-related medical conditionin men. In the last 20 years, alternative therapies, especially those based on herbs, are increasingly preferred. The most popularly consumed herb is Serenoa repens, a plant growing in the subtropical south-eastern United States which has shown very efficient results compared to pharmacological conventional treatments both in terms of cost and risks associated with them. Nevertheless, the same trial found no difference between S. repens and placebo according to the American Urological Association Symptom Score Index. As more and more consumers are turning increasingly towards natural therapies, it would be appropriate to promote the recognition of the value of other medicinal plants with potential applicability through comprehensive research. For this purpose, a descriptive comparison between several South-American plants little publicised in the pharmaceutical market is presented to slightly narrow the gap between the reliable evidence-based and popular information for consumers and the pharmaceutical industry.Experimental: With this approach, a review of the literature was conducted through an electronic consultation of two databases, Science Direct and Google Scholar™.Results: This narrative review highlights the wide range of natural medicines available for controlling the inflammatory symptoms of the lower urinary tract, which could be more explored from a pharmacological and chemical point of view.Recommended applications/industries: The future use of natural products requires further investment in pre-clinical research and in clinical trials that investigate stability and a profitable pharmacokinetic/pharmacodynamic ratio. Although they are well tolerated and used daily by South American populations, the industry's proper commercial focus on these natural remedies cannot be separated from appropriate phyto-vigilance actions promoted
Manuscript profile
Background & Aim: A combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana leaves are used for the treatment of benign prostatic hyperplasia, but there is no scientific data on its safety level and effects on vital organs and biochemical parameter More
Background & Aim: A combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana leaves are used for the treatment of benign prostatic hyperplasia, but there is no scientific data on its safety level and effects on vital organs and biochemical parameters. This study investigated the effects of a combined ethanol extract of Spermacoce radiata and Hypselodelphyspoggeana leaves (CESHL) on the lipid profile and kidney function of benign prostatic hyperplasia (BPH) induced rats.Experimental: A total of 21 rats were used for the acute toxicity study, while 30 were randomly distributed into five groups comprising six rats each (n = 6) for the BPH study. Group 1 served as normal control, while group 2 was BPH control that received 5 mg/kg of testosterone propionate/day for 28 consecutive days without treatment. Groups 3 – 5 received 5 mg/kg of testosterone propionate/day for 28 days but after an hour, they treated with 5 mg/kg of finasteride, 200 and 600mg/kg of CESHL/day, respectively, for 28 days.Results: The acute toxicity result of CESHL indicated no mortality or any sign of toxicity. Administration of the extract caused a significant reduction (p<0.05) of theprostate weight, triacylglycerol, cholesterol, low-density lipoprotein (LDL-C), urea and creatinine concentrations in the treated groups when compared to the BPH control. A significant increase (P<0.05) in High-Density Lipoprotein (HDL) concentration was observed in all treated groups when compared to the BPH control group. Histological outcomes of rats’ kidneys corroborated these findings.Recommended applications/industries: These results indicate that the combined extracts possess antilipidemic and nephroprotective effects, which might help in the management of complications that might arise during BPH.
Manuscript profile
Background: Although voiding symptoms are classically related to BPH, as many as 50% of patients can experience irritative symptoms. We compared efficacy of tamsulosin with or without tolterodine in the treatment of patients with symptomatic BPH (benign prostatic More
Background: Although voiding symptoms are classically related to BPH, as many as 50% of patients can experience irritative symptoms. We compared efficacy of tamsulosin with or without tolterodine in the treatment of patients with symptomatic BPH (benign prostatic hyperplasia).
Methods: seventy six patients who fulfilled the inclusion/ exclusion criteria were randomly divided into two groups of tamsulosin monotherapy (0/4 mg/day until 12 weeks) versus tamsulosin (0/4 mg/day until 12 weeks) and Tolterodine (2mg BID for 4 weeks) combination therapy. Therapeutic efficacy was analyzed using international prostate symptom score (IPSS) before and after 4 weeks of treatment.
Results: Total IPSS was significantly improved in both groups. Although Combination therapy group showed better improvement in all Lower urinary tract symptoms, but the difference between 2 groups was significant considering complete emptying of bladder, voiding duration less than 2 hours and weak stream (P<0/05).
Conclusion: Addition of Tolterodin to Tamsulosin is effective in improving lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Manuscript profile
Sanad
Sanad is a platform for managing Azad University publications
